CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed
Drug / intervention
Spironolactonedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00317954
NCT00317954Phase 4Completed
CompareCT.gov

Spironolactone in Diabetic Nephropathy

Steno Diabetes Center Copenhagen·interventional·Posted Apr 25, 2006·Updated Apr 25, 2006

In Brief

A Phase 4 clinical trial evaluating Spironolactone for Diabetic Nephropathy. Completed, across 1 site.

Detailed Summary

The aim of the study was to evaluate the renoprotective effect (i.e. albuminuria- and bloodpressure lowering effect) of spironolactone 25 mg o.d. in type 1 and type 2 diabetic patients with albuminuria despite recommended antihypertensive treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetic Nephropathy
CountriesDenmark
Collaborators--

Timeline

Phase 4CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 25, 2006
Enrollment StartSep 1, 2003
Study CompletionJul 1, 2005
TodayJul 2, 2026
Posted 20.2 years ago

Interventions

Spironolactonedrug